BioCell Technology has begun a new clinical study of its patented Collagen II product in order to assess its effects on the treatment of osteoarthritis.
BioCell Collagen II is derived from the sternums of young chickens and then hydrolysed for maximum absorption. BioCell's production process enables the product to contain a high concentration of collagen type II, the most abundant structural protein found in articular cartilage.
BioCell said the product was also rich in glycosaminoglycans, chondroitin sulphate, glucosamine sulfate, hyaluronic acid and a newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP).
The company claims that these components can help keep joints healthy by promoting new cartilage synthesis and by reducing oxidative damage to the joints, and the clinical study will aim to support this claim.